MINNEAPOLIS– Vensana Capital, a venture capital and growth equity firm specializing in medical technology, has announced the addition of two seasoned healthcare leaders to its team. Maria Berkman, MD, has joined the firm as Partner, and Ross “Rusty” Segan, MD, has been appointed as Venture Partner.
Berkman brings more than a decade of investment experience from her tenure at Broadview Ventures, where she most recently served as Director and Head of the MedTech practice, as well as Managing Director of the affiliated Longview Ventures. At Broadview, she played a key role in shaping investment strategy, building teams, and growing the firm’s portfolio, contributing to the success of nearly 20 medical technology companies, including notable exits such as Apama Medical and CardiAQ. Her background includes clinical training at Newton-Wellesley Hospital and dual MD/MBA degrees from UCLA.
“Maria is an experienced investor, a trusted advisor to her portfolio companies, and a respected leader within the medtech ecosystem,” said Dr. Justin Klein, Managing Partner at Vensana. “We’ve long admired her work and are thrilled to have her join our team.”
Joining Berkman is Dr. Rusty Segan, a veteran medtech executive and former physician who brings over 25 years of experience spanning government, industry, and clinical practice. Segan previously served as Director of the Office of Product Evaluation and Quality at the FDA’s Center for Devices and Radiological Health. His industry roles include Chief Medical Officer positions at Olympus and Johnson & Johnson Medical Devices, along with leadership positions at Covidien. A former U.S. Army Medical Corps officer and recipient of the Meritorious Service Medal, Segan also holds an MD from Rutgers and an MBA from NYU Stern.
“Rusty is a highly regarded clinician and executive with a proven ability to connect science, medicine, and strategy to drive innovation,” said Klein.
Vensana Managing Partner Kirk Nielsen noted that the appointments reflect the firm’s commitment to assembling one of the most experienced investment teams in the medtech space. “Since launching Vensana in 2019, we’ve set out to build a team with deep sector expertise. The addition of Maria and Rusty is a major step in that journey,” Nielsen said.
With these new additions, Vensana aims to further its mission of backing transformative medtech companies that advance patient care worldwide.
